You are here

Article info

Article menu

Download PDFPDF

XML
Research Article
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition

Authors

  • Wendy Mao Department of Oncology, Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins University School of Medicine 21287 Baltimore MD USA Columbia Center for Translational ImmunologyColumbia University Medical Center 10032 New York NY USA PubMed articlesGoogle scholar articles
  • Ali Ghasemzadeh Department of Oncology, Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins University School of Medicine 21287 Baltimore MD USA Columbia Center for Translational ImmunologyColumbia University Medical Center 10032 New York NY USA PubMed articlesGoogle scholar articles
  • Zachary T. Freeman Unit for Laboratory Animal Medicine (ULAM), Michigan MedicineUniversity of Michigan 48109 Ann Arbor MI USA Rogel Cancer Center, Michigan MedicineUniversity of Michigan 48109 Ann Arbor MI USA PubMed articlesGoogle scholar articles
  • Aleksandar Obradovic Columbia Center for Translational ImmunologyColumbia University Medical Center 10032 New York NY USA Columbia University Systems Biology, Herbert Irving Cancer Research CenterColumbia University Medical Center 10032 New York NY USA PubMed articlesGoogle scholar articles
  • Matthew G. Chaimowitz Columbia Center for Translational ImmunologyColumbia University Medical Center 10032 New York NY USA PubMed articlesGoogle scholar articles
  • Thomas R. Nirschl Department of Oncology, Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins University School of Medicine 21287 Baltimore MD USA PubMed articlesGoogle scholar articles
  • Emily McKiernan Columbia Center for Translational ImmunologyColumbia University Medical Center 10032 New York NY USA PubMed articlesGoogle scholar articles
  • Srinivasan Yegnasubramanian Department of Oncology, Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins University School of Medicine 21287 Baltimore MD USA PubMed articlesGoogle scholar articles
  • Charles G. Drake Columbia Center for Translational ImmunologyColumbia University Medical Center 10032 New York NY USA Department of UrologyColumbia University Medical Center 10032 New York NY USA Herbert Irving Comprehensive Cancer Center, Division of Hematology / OncologyColumbia University Medical Center 177 Fort Washington Avenue, Suite 6GN-435 10032 New York NY USA PubMed articlesGoogle scholar articles

Citation

Mao W, Ghasemzadeh A, Freeman ZT, et al
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Journal for ImmunoTherapy of Cancer 2019;7:277. doi: 10.1186/s40425-019-0758-y
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.